research Local infusion of infliximab for the treatment of acute joint inflammation
Co-trimoxazole may help treat autoimmune diseases.
Search
for
Sort by
Research
690-720 / 1000+ results
research Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases
Rimegepant causes more nausea and skin issues, while ubrogepant causes more muscle issues; personalized treatment is important.
research Trapa bispinosa Roxb. Pericarp Extract Exerts 5α-Reductase Inhibitory Activity in Castrated Benign Prostatic Hyperplasia Model Mice
Trapa bispinosa Roxb. extract may help reduce prostate size and cell growth in BPH.
research COMPARISON OF EFFICACY OF BARICITINIB VERSUS METHOTREXATE THERAPY IN THE TREATMENT OF SEVERE ALOPECIA AREATA
Baricitinib works better than methotrexate for severe alopecia areata.
research Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
research Preparation of finasteride by selective dehydrogenation using IBX
The method produces finasteride with a 92% yield.
research Do finasteride and bicalutamide affect blood glucose levels in diabetics?
Finasteride and bicalutamide can affect blood sugar, so diabetics need monitoring.
research Do finasteride and bicalutamide affect blood glucose levels in diabetics?
Finasteride and bicalutamide can affect blood sugar, so diabetics need monitoring.
research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
research Treatment of severe alopecia areata with oral tofacitinib: A case series
Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
research Finasteride plus doxazosin combination tops in BPH
research Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis
Leflunomide and methotrexate are similarly effective for rheumatoid arthritis but have different side effects.
research Acupoint injection of metoclopramide on functional dyspepsia clinical observation and nursing experience
Zusanli acupoint injection of metoclopramide effectively treats functional dyspepsia.
research Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure
Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
research 43018 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 1.6 years and up to 3.6 Years of Exposure
Baricitinib is a safe and effective treatment for severe alopecia areata.
research Downregulation of nuclear factor-kappaB activation in human keratinocytes by melanogenesis inhibitors
Melanogenesis inhibitors like kojic acid and niacinamide can reduce inflammation and pigment production in skin cells.
research Tofacitinib for the treatment of alopecia areata and variants in adolescents
Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
research Tofacitinib for the treatment of alopecia areata in preadolescent children
Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
research Combined Sabal and Urtica extract vs finasteride in BPH (Alken stage I–II)
Sabal and Urtica extract works as well as finasteride for treating BPH, with fewer side effects.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
research Natural Product-InspiredBis(trifluoromethyl) PhenylHydroxycinnamate Derivatives as Promising Nonsteroidal Inhibitorsof Human Steroid 5α-Reductase Type-1: Synthesis, InVitro, and In Silico Studies
Certain hydroxycinnamate derivatives may effectively inhibit enzymes linked to hair loss with low toxicity.
research Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.
research Tofacitinib therapy for the treatment of alopecia areata: Report of 11 patients
Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.
research Prescribers alerted to potential adverse effects of finasteride and montelukast
research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
research Real‐life effectiveness and safety of baricitinib in adults with alopecia areata: A multicentre study
Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
research Adherence to topical hydrocortisone 17-butyrate 0.1% in different vehicles in adults with atopic dermatitis
Adults with atopic dermatitis showed similar adherence to different forms of hydrocortisone cream, but actual use varied despite self-reports of near-perfect usage.